News

background shapes
January 30, 2024
Defender Pharmaceuticals Receives Complete Response Letter from the U.S. Food and Drug Administration for its Intranasal Scopolamine (DPI-386) New Drug Application for the Prevention of Nausea and Vomiting Induced by Motion in Adults
VIEW Press Release
October 24, 2023
Defender Pharmaceuticals Announces Collaboration with NASA on Two Phase 2 Clinical Trials Investigating DPI-386’s Ability to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
VIEW Press Release
September 26, 2023
FDA Accepts Defender Pharmaceuticals’ New Drug Application for Intranasal Scopolamine Gel
VIEW Press Release
August 22, 2023
Efficacy of Intranasal Scopolamine HBr (INSCOP, DPI-386) for the prevention of vomiting or the need for rescue medication associated with motion.
VIEW Poster
August 11, 2023
Defender Pharmaceuticals Phase 3 Motion Sickness Trial Results Selected for Presentation at 2023 Military Health System Research Symposium (MHSRS)
VIEW Press Release
August 1, 2023
Defender Pharmaceuticals Announces Exclusive License Agreement with the U.S. Army for the Development of Products to Treat Tropical Diseases
VIEW Press Release
July 26, 2023
Defender Pharmaceuticals Announces Submission of New Drug Application to FDA with Intranasal Scopolamine for Prevention of Nausea and Vomiting Induced by Motion in Adults
VIEW Press Release
July 18, 2023
St. Louis-based Defender Pharmaceuticals, with $70M in funding, eyes approval for lead drug candidate
VIEW Article
June 5, 2023
Defender Pharmaceuticals Reports Positive Results from Pivotal Phase III ClinicalTrial of Intranasal Scopolamine for the Prevention of Nausea and Vomiting Induced by Motion
VIEW Press Release
February 22, 2022
A Randomized, Double-Blind Placebo-Controlled Phase III Study of the Efficacy and Safety of DPI-386 Nasal Gel Compared to Current Standard of Care for Prevention of Motion Sickness
VIEW Poster

DPI-001 2023-02